[go: up one dir, main page]

ES2486845T3 - Torio-227 para ser usado en radioterapia de enfermedad de partes blandas - Google Patents

Torio-227 para ser usado en radioterapia de enfermedad de partes blandas Download PDF

Info

Publication number
ES2486845T3
ES2486845T3 ES04727587.0T ES04727587T ES2486845T3 ES 2486845 T3 ES2486845 T3 ES 2486845T3 ES 04727587 T ES04727587 T ES 04727587T ES 2486845 T3 ES2486845 T3 ES 2486845T3
Authority
ES
Spain
Prior art keywords
thorium
addressing
effective amount
tissue disease
soft tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04727587.0T
Other languages
English (en)
Inventor
Roy Larsen
Oyvind Bruland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AS
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Algeta ASA filed Critical Algeta ASA
Application granted granted Critical
Publication of ES2486845T3 publication Critical patent/ES2486845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

Utilización de una cantidad terapéuticamente eficaz de un complejo de torio-227 y complejante que se dirige a las partes blandas, para la fabricación de un medicamento para el tratamiento de enfermedad de partes blandas en un sujeto mamífero, en donde dicha cantidad eficaz es tal que al usarla se genera in vivo una cantidad aceptablemente no mielotóxica de radio-223 por desintegración nuclear del torio-227 administrado, y en donde el torio-227 está conjugado a un complejante de direccionamiento, en donde el complejante comprende un resto de direccionamiento con bioafinidad, en donde dicho resto de direccionamiento es uno que sirve para dirigir el complejo a la parte blanda a tratar, excluidos los osteótropos, liposomas y anticuerpos o fragmentos de anticuerpo conjugados a folato, y en donde la cantidad terapéuticamente eficaz de torio-227 es de al menos 25 kBq/kg.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
E04727587
30-07-2014
Tabla 6
Parámetros
Toxicidad Dosis única / kBq/kg Retratamiento Varias dosis / kBq/kg
Grados CTC
46 93 163 213 250 5 x 50 2 x 125
n = 5
n = 5
n = 5
n = 5
n = 5
n = 2 n = 3 n = 3
Plaquetas
0 5 5 4 5 2 2 2 3
1
0 0 1 0 3 0 1 0
Neutrófilos
0 4 3 3 2 2 2 1 3
1
0 1 0 1 0 0 0 0
2
1 1 1 2 2 0 2 0
3
0 0 1 0 1 0 0 0
Glóbulos blancos
0 4 4 3 2 2 2 1 2
1
0 0 0 0 0 0 0 0
2
1 1 1 2 2 0 2 1
3
0 0 1 1 1 0 0 0
Hemoglobina
0 4 2 4 2 2 1 0 0
1
0 2 0 2 3 1 2
1
2
1 1 1 1 0 0 1
2
16

Claims (1)

  1. imagen1
    imagen2
ES04727587.0T 2003-04-15 2004-04-15 Torio-227 para ser usado en radioterapia de enfermedad de partes blandas Expired - Lifetime ES2486845T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0308731 2003-04-15
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (1)

Publication Number Publication Date
ES2486845T3 true ES2486845T3 (es) 2014-08-19

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04727587.0T Expired - Lifetime ES2486845T3 (es) 2003-04-15 2004-04-15 Torio-227 para ser usado en radioterapia de enfermedad de partes blandas

Country Status (18)

Country Link
EP (1) EP1617876B1 (es)
JP (2) JP5006032B2 (es)
KR (2) KR20060015507A (es)
CN (1) CN100586484C (es)
AU (1) AU2004229218B2 (es)
BR (1) BRPI0409387B8 (es)
CA (1) CA2522148C (es)
CY (1) CY1115407T1 (es)
DK (1) DK1617876T3 (es)
EA (1) EA008195B1 (es)
ES (1) ES2486845T3 (es)
IL (1) IL171148A (es)
MX (1) MXPA05010804A (es)
NO (1) NO332931B1 (es)
NZ (3) NZ595758A (es)
PL (1) PL1617876T3 (es)
PT (1) PT1617876E (es)
ZA (1) ZA200507983B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595758A (en) * 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
US11291680B2 (en) 2016-12-15 2022-04-05 Société des Produits Nestlé S.A. Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089553B2 (ja) * 1989-06-19 1996-01-31 アクゾ・エヌ・ヴエー α粒子放出を使用する放射免疫療法
JPH07505886A (ja) * 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
CN1073860C (zh) * 1998-08-20 2001-10-31 中国核动力研究设计院 用于骨肿瘤治疗或诊断的放射性药物药盒的制备方法
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
HUP0203743A2 (en) * 2000-02-25 2003-02-28 R Keith Frank Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) * 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
NZ595758A (en) * 2003-04-15 2013-02-22 Algeta As Thorium-227 for use in radiotherapy of soft tissue disease

Also Published As

Publication number Publication date
AU2004229218A1 (en) 2004-10-28
EA008195B1 (ru) 2007-04-27
CN100586484C (zh) 2010-02-03
JP2012051942A (ja) 2012-03-15
CA2522148A1 (en) 2004-10-28
JP5006032B2 (ja) 2012-08-22
CY1115407T1 (el) 2017-01-04
BRPI0409387B8 (pt) 2021-05-25
AU2004229218B2 (en) 2009-05-07
NZ595758A (en) 2013-02-22
BRPI0409387B1 (pt) 2021-05-11
KR20060015507A (ko) 2006-02-17
NO332931B1 (no) 2013-02-04
KR101274867B1 (ko) 2013-06-13
EP1617876B1 (en) 2014-05-14
IL171148A (en) 2013-12-31
JP2006523664A (ja) 2006-10-19
JP5468597B2 (ja) 2014-04-09
KR20110022743A (ko) 2011-03-07
PL1617876T3 (pl) 2015-03-31
NZ543044A (en) 2010-04-30
BRPI0409387A (pt) 2006-04-18
ZA200507983B (en) 2007-03-28
HK1094150A1 (zh) 2007-03-23
NO20055390D0 (no) 2005-11-15
DK1617876T3 (da) 2014-07-21
NZ606996A (en) 2014-08-29
CN1805760A (zh) 2006-07-19
PT1617876E (pt) 2014-08-04
CA2522148C (en) 2010-07-13
EA200501456A1 (ru) 2006-06-30
EP1617876A1 (en) 2006-01-25
NO20055390L (no) 2006-01-16
MXPA05010804A (es) 2006-03-09

Similar Documents

Publication Publication Date Title
Wang et al. Effect of shock wave therapy on acute fractures of the tibia: a study in a dog model.
Wharam et al. Localized orbital rhabdomyosarcoma: an interim report of the Intergroup Rhabdomyosarcoma Study Committee
Ueno et al. A clinicopathologic study of ameloblastoma
Franzén et al. Oral implant rehabilitation of patients with oral malignancies treated with radiotherapy and surgery without adjunctive hyperbaric oxygen.
Brusamolino et al. Treatment of early-stage Hodgkin's disease with four cycles of ABVD followed by adjuvant radio-therapy: analysis of efficacy and long-term toxicity
Mark et al. Fibrosarcoma of the head and neck: the UCLA experience
ES2486845T3 (es) Torio-227 para ser usado en radioterapia de enfermedad de partes blandas
Silverberg et al. Osteoclastoma‐like giant cell tumor of the thyroid. Report of a case with prolonged survival following partial excision and radiotherapy
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
ATE454166T1 (de) Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern
ES2080837T3 (es) Tratamiento de estados y enfermedades.
Lee et al. Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU
COLEMAN Chemotherapy for large-cell lymphoma: optimism and caution
ES2089027T3 (es) Forma de dosificacion transmucosica.
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
Pfuetze et al. The first clinical trial of streptomycin in human tuberculosis
Frankenthaler et al. Fibrosarcoma of the head and neck
Mastrangelo et al. Etiological periodontal treatment with and without low-level laser therapy on IL-1β level in gingival crevicular fluid: An in vivo multicentric pilot study
DeVita Jr A selective history of the therapy of Hodgkin's disease.
MX2022016406A (es) Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib.
MAEDA et al. High-energy, low-dose radiation therapy for aneurysmal bone cyst: report of a case
Schultz et al. Management of presumptive or proven Hodgkin's disease of the liver: A new radiotherapy technique
RU2005131578A (ru) Аплидин для лечения множественной миеломы